All In Biotech

Free tool

FAERS Monitor: Allegra-D 24 Hour Allergy and Congestion

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021704 or its brand name (Allegra-D 24 Hour Allergy and Congestion, Fexofenadine Hydrochloride, Pseudoephedrine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

49

Serious

12

24% of reports

Hospitalization

8

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product quality issue8
  • drug ineffective7
  • diarrhoea4
  • dizziness4
  • extra dose administered4
  • headache4
  • nausea4
  • chest discomfort2
  • constipation2
  • ear pain2
  • fatigue2
  • gastrointestinal disorder2
  • hypersensitivity2
  • insomnia2
  • malaise2

Reports by year received

View as table
YearReports
20091
20122
201411
201513
20162
20171
20183
20222
20233
20243
20255
20263

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,110 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ear pain244.211.447
extra dose administeredSignal442.416.6123
product quality issueSignal825.313.4164
gastrointestinal disorder29.62.58
chest discomfort28.42.27
hypersensitivity24.61.23
constipation23.91.02
dizzinessSignal43.41.35
insomnia23.20.81
headache42.71.13
diarrhoea42.71.03
drug ineffectiveSignal72.31.14
nausea42.20.82
malaise22.00.50
fatigue21.10.30

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.